

## Mouse CPT2 siRNA

Catalogue No.:abx912725

siRNA to inhibit CPT2 expression using RNA interference.

This product is provided as three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

| Target:              | CPT2  |                      |                             |                         |                        |
|----------------------|---|----------------------|-----------------------------|-------------------------|------------------------|
| Reactivity:          | Mouse   |                      |                             |                         |                        |
| Tested Applications: | RNAi  |                      |                             |                         |                        |
| Host:                | Synthetic   |                      | C                           | 6                       |                        |
| Recommended          | Optimal dilutions/concentrations should be determined by the end user.                            |                      |                             |                         |                        |
|                      | Plate         Final Medium         Final siRNA         20 μM siRNA         Lipofectamine 2000     |                      |                             |                         |                        |
| dilutions:           | (wells)   | Volume (ml)          | Concentration (nM)          | Volume (µl)             | Volume (µl)            |
|                      | ()  | ,                    | 100                         | 0.5                     | 0.25                   |
|                      | 96  | 0.1                  | 50                          | 0.25                    | 0.25                   |
|                      |   |                      | 10                          | 0.05                    | 0.25                   |
|                      |   | 0.5                  | 100                         | 2.5                     | 1                      |
|                      | 24  | 0.5                  | 50                          | 1.25                    | 1                      |
|                      |   |                      | 10<br>100                   | 0.25<br>5               | 1<br>2                 |
|                      | 12  | 1                    | 50                          | 2.5                     | 2                      |
|                      | 12  |                      | 10                          | 0.5                     | 2                      |
|                      |   |                      | 100                         | 10                      | 5                      |
|                      | 6   | 2                    | 50                          | 5                       | 5                      |
|                      |   |                      | 10                          | 1                       | 5                      |
| Form:                | Lyophilized   | d                    |                             |                         |                        |
|                      | 2.1   |                      |                             |                         |                        |
| Purity:              | > 97%   |                      |                             |                         |                        |
|                      | <u>.</u>  |                      |                             |                         |                        |
| Quality Control:     | Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate |                      |                             |                         |                        |
|                      | coupling e  | fficiency. The oligo | is subsequently purified    | by affinity-solid phas  | e extraction. The      |
|                      | annealed I  | RNA duplex is furt   | ner analyzed by mass spe    | ectrometry to verify th | e exact composition of |
|                      | the duplex  | Each lot is comp     | ared to the previous lot by | mass spectrometry       | to ensure maximum lot- |
|                      |   | -                    |                             |                         |                        |
|                      | to-lot cons   | istency.             |                             |                         |                        |
| Storage:             | Shipped at 4 °C. Store at -20 °C for up to one year.  |                      |                             |                         |                        |
| UniProt Primary AC:  | P52825 ( <u>UniProt</u> , <u>ExPASy</u> )   |                      |                             |                         |                        |
| Gene Symbol:         | CPT2  |                      |                             |                         |                        |

## Datasheet Version: 1.0.0

Revision date: 17 Apr 2025



| GenelD:             | <u>12896</u>   |
|---------------------|--|
| NCBI Accession:     | NM_009949.2  |
| KEGG:               | mmu:12896  |
| Specificity:        | CPT2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.  |
| Note:               | This product is for research use only.   |
| Directions for use: | <ul> <li>1. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube.</li> <li>2. Resuspend the siRNA oligos to an appropriate concentration with DEPC water (e.g. resuspend one vial of 5 nmol siRNA oligo in 250 μl of DEPC water for a final concentration of 20 μM).</li> <li>3. Transfect with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis.</li> </ul> |

v1.0.0